US8006771062 - Common Stock
0.45 -0.03 (-7.22%)
After market: 0.47 +0.02 (+4.44%)
Curious about the stocks that are showing activity after the closing bell on Tuesday?
Sangamo Therapeutics Inc.’s cost cuts didn’t hurt just the roughly 162 US workers who lost their jobs this month. It’s also a blow to Jerry Walter, who’s lost five family members and suffered kidney, lung, hearing and heart damage from a rare disease.
RBC Capital downgrades Sangamo Therapeutics (SGMO) due to workforce cuts and program pauses, lowering price target to $2 from $6. Read more here.
Sangamo Therapeutics (SGMO) sells 6 million shares for $3 million, according to recent disclosure.
Treating rare diseases is a tough but potentially lucrative business. With clinical trials coming due, here are three stocks to buy.
We're starting the final day of trading this week with a dive into the biggest pre-market stock movers worth watching for Friday!
BofA Securities has downgraded Sangamo Therapeutics (SGMO) to underperform as the company is undergoing a restructuring to address cash concerns. Read more here.